Cancer Aneuploidy May Predict Response to Immunotherapy in Patients With NSCLC
Lower levels of cancer aneuploidy were associated with more favorable outcomes after immune checkpoint inhibition in patients with non-small cell lung cancer (NSCLC), according to data presented by Alessi et al at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 ( Abstract 26).